News
In Memoriam: James M. Slater, pioneer of proton therapy, transformed cancer treatment
January 02, 2019
James M. Slater, MD, whose determination to improve the quality of life for patients undergoing cancer treatment inspired him to use proton therapy for patient care and to champion and oversee creation of the world's first hospital-based proton treatment center at Loma Linda University Health, dies Dec 26. He was 89.
Children in developing countries can benefit from proton therapy
February 22, 2018
Children with cancer are arguably set to benefit most from proton therapy as the number of clinics worldwide continues to grow. Steep dose gradients enable superior sparing of healthy tissue compared to photons, reducing the lifetime risk of radiation-induced cancer and increasing survival.
Provision Healthcare successfully treats first patients with new proton therapy system
February 17, 2018
Provision Healthcare has successfully treated its first patients using Blount County-based ProNova Solutions' newly developed SC360 proton therapy system at the Provision CARES Cancer Center in Knoxville.
Proton therapy shows promise for recurrent lung cancer
March 20, 2017
Intensity-modulated proton therapy conferred durable control with minimal toxicity among patients with recurrent thoracic cancer, according to results of a retrospective study presented at the Multidisciplinary Thoracic Cancers Symposium.
Proton therapy represents a niche, but growing market.
March 08, 2017
The global particle therapy device market (mainly proton therapy devices) reached $750 million in 2015. The market growth has accelerated during the last five years, showing an average annual growth rate of 19 percent from 2010 to 2015. For the first time, the proton therapy world market is anticipated to reach over $1 billion in 2018, one year sooner than previously estimated. It is projected to reach between $3.5 billion and $6.6 billion by 2030, with 1,200 to 1,800 particle therapy treatment rooms open to patients worldwide.
Particle therapy offers safer re-irradiation
October 26, 2016
Head-and-neck squamous cell carcinoma (HNSCC) is a particularly difficult cancer to cure, with a post-treatment recurrence risk of up to 30% and a 12–13% five-year incidence of second new tumors. Patients treated for recurrence with surgical resection plus re-irradiation can experience long-term disease control, but rates of severe toxicity are high. Reducing the risk of radiation-induced complications is an essential goal.
How Is Proton Therapy Research Benefiting Pediatric Cancer and Multimodal Treatments? Q&A with Dr. Perentesis
October 19, 2016
In this Q&A, Dr. Perentesis shares his thoughts on some of the benefits of proton therapy research including reducing side effects and secondary cancers, as well as improving long-term outcomes
U.S. proton therapy market to reach $1 billion by 2022 with 38 facilities
October 14, 2016
According to the report, by 2022, the US will have 38 proton therapy centers. Consequently, the market will attain revenue of around US$ 1 Billion by 2022, growing at a CAGR of over 16% during the forecast period (2015-2022).
Proton Therapy World Market is expanding faster
October 07, 2016
The global particle therapy devices market (mainly proton therapy devices) reached US$ 750 million in 2015. Market growth has accelerated during the last five years, showing an average annual growth rate of 19% from 2010 to 2015. For the first time, the proton therapy world market is anticipated to reach over US$ 1 billion in 2018, one year sooner than previously estimated. It is projected to reach between US$ 3.5 and 6.6 billion by 2030, with 1,200 to 1,800 particle therapy treatment rooms open to patients worldwide.
Utilizing Multi-Field Optimization with IMPT for Head and Neck Cancer Treatment
September 07, 2016
Head and neck cancers can be challenging to treat as they are often adjacent to multiple critical structures, such as the optic nerves or the brain stem. At Scripps, we are successfully treating these complex cancers using multi-field optimization intensity-modulated proton therapy (MFO-IMPT) and CBCT.